Volume 25, Issue 11, November 2023

What is an isocitrate dehydrogenase-mutated central nervous system World Health Organization grade 2 glioma, or who should receive vorasidenib?

• Extract
• View article

The INDIGO trial: Precision medicine finally comes to glioma

• Extract
• View article

Optimizing preclinical pediatric low-grade glioma models for meaningful clinical translation

• Abstract
• View article

Watching the clock in glioblastoma

• Abstracts
• View article

Upstream open reading frame-encoded MP31 disrupts the mitochondrial quality control process and inhibits tumorigenesis in glioblastoma

• Abstracts
• View article
• Supplementary data

Sialic acid metabolism orchestrates transcellular connectivity and signaling in glioblastoma

• Abstract
• View article
• Supplementary data

EPIC-0307-mediated selective disruption of PRADX–EZH2 interaction and enhancement of temozolomide sensitivity to glioblastoma via inhibiting DNA repair and MGMT

• Abstract
• View article
• Supplementary data

M2 isoform of pyruvate kinase rewires glucose metabolism during radiation therapy to promote an antioxidant response and glioblastoma radioresistance

• Abstract
• View article
• Supplementary data

Chimeric antigen receptor T cell-based targeting of CD317 as a novel immunotherapeutic strategy against glioblastoma

• Abstract
• View article
• Supplementary data

Nonstructural maintenance of chromatin condensin I complex subunit G promotes the progression of glioblastoma by facilitating Poly (ADP-ribose) polymerase 1-mediated E2F1 transactivation

• Abstracts
• View article
• Supplementary data

Integrated molecular analysis reveals hypermethylation and overexpression of HOX genes to be poor prognosticators in isocitrate dehydrogenase mutant glioma

• Abstract
• View article
• Supplementary data

Prognostic value of integrative genomic approaches for IDH-mutant gliomas

• Extract
• View article

Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology

• Abstract
• View article
• Supplementary data

Intracranial injection of natural killer cells engineered with a HER2-targeted chimeric antigen receptor in patients with recurrent glioblastoma

• Abstract
• View article
• Supplementary data

Chimeric antigen receptors in the brain: Can we tackle glioblastoma with engineered NK cells?

• Extract
• View article

PNOC015: Repeated convection-enhanced delivery of MTX110 (aqueous panobinostat) in children with newly diagnosed diffuse intrinsic pontine glioma

• Abstract
• View article
• Supplementary data

LOGGIC Core BioClinical Data Bank: Added clinical value of RNA-Seq in an international molecular diagnostic registry for pediatric low-grade glioma patients

• Abstract
• View article
• Supplementary data

“LOGGIC” of RNA-sequencing in enhancing diagnoses of pediatric low-grade gliomas

• Extract
• View article

Targeting cholesterol homeostasis through inhibiting SREBP-2: An Achilles’ heel for glioblastoma

• Extract
• View article

Reply to “Targeting cholesterol homeostasis through inhibiting: An Achilles’ heel for glioblastoma?”

• Extract
• View article

Correction to: Cancer-associated SMARCAL1 loss-of-function mutations promote alternative lengthening of telomeres and tumorigenesis in telomerase-negative glioblastoma cells

• Extract
• View article

Correction to: HGG-16. COMPARATIVE ANALYSIS OF AUTOPHAGY IN DRUG RESPONSES AND AGGRESSIVE BEHAVIOR OF ADULT VERSUS PEDIATRIC GLIOMA CELL LINES

• Extract
• View article

Correction to: Mapping pediatric brain tumors to their origins in the developing cerebellum

• Extract
• View article

Forthcoming Meetings

• Extract
• View article